1. Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo....

Rybelsus in combination with standard T2DM therapy reduced the risk of major cardiovascular events by 14% in patients with diabetes...

Patients with wet age-related macular degeneration receiving CLS-AX achieved stable visual acuity, and retinal thickness for up to six months....

FluMist is an efficacious and safely tolerated intranasal influenza vaccine. FluMist has gained approval from the FDA for self-administration by...

Afami-cel (Tecelra) is the first genetically engineered T-cell receptor therapy for synovial sarcoma Afami-cel demonstrated an overall response rate of...